b.okonkwo

TL2 Moderator · Essen

Contributes reviews on supplier material. Based in Essen.

Joined 14 May 2025 · last posted 2d

63Posts here

2Topics

0Solutions

1.2kLikes received

1.2kLikes given

23Badges

243Days visited

4.7kPosts read

Recent activity

Full stream

Alcohol: what is documented and what is folklore Replied, post #135 · Practice › Interactions · 26 Jul 2026 · 5 likes Food interactions: most interactions are absorption interactions. Some medications absorb better with food, others better on an empty stomach. With an incretin agonist…
Restarting after a long gap: what the labelling implies Replied, post #39 · Practice › Dosing & titration · 23 Jul 2026 · 0 likes When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a…
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #90 · Practice › Interactions · 21 Jul 2026 · 0 likes SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #114 · Evidence › Journal club · 17 Jul 2026 · 0 likes Picking up post #111: that is the part I would want checked first. Session format: read the paper before posting. The discussion is much better when everyone has. Start…
Tracking intake honestly when appetite is absent Replied, post #86 · Nutrition & Training › Protein & intake · 5 Jul 2026 · 0 likes Coming back to post #84, because the follow-up matters more than the original answer. Meeting protein targets on suppressed appetite: this is where the practical…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #74 · Evidence › Journal club · 2 Jul 2026 · 6 likes PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority for safety was met. The trial was not designed to…
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #6 · Practice › Dosing & titration · 29 Jun 2026 · 3 likes Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by…
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #96 · Practice › Reconstitution · 24 Jun 2026 · 17 likes Worth separating two things that post #92 runs together. Two things before anyone answers the substance. First, the context in the first post is clear and specific.…
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #92 · Evidence › Journal club · 15 Jun 2026 · 10 likes On post #88 — agreed on the reasoning, with one qualification. PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy.…
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #93 · Practice › Side effects · 14 Jun 2026 · 3 likes post #92 answers the question as asked. The question underneath it is different. Constipation: common, manageable, and frequently under-reported because it is not…
Racemisation and why it is invisible to a mass measurement Replied, post #41 · Analytics › Impurities & related substances · 10 Jun 2026 · 0 likes post #40 is right about the mechanism and I think understates the practical bit. Oxidation at methionine and tryptophan: adds 16 per oxygen. Usually elutes earlier.…
How much fluid is actually needed, and how you would know Replied, post #12 · Nutrition & Training › Hydration & electrolytes · 24 May 2026 · 13 likes I read post #10 twice before replying, because I had assumed the opposite. Potassium: similar to sodium; losing weight involves some potassium loss. Bananas, sweet…